ClinicalTrials.gg
CompletedNCT00672620Updated Dec 18, 2013Results posted

Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder

A Phase 3 interventional study of Vortioxetine and Duloxetine in Major Depressive Disorder, sponsored by Takeda. Completed at 38 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2013-12-18.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
611
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing vortioxetine in Depressive Disorder, Major — 1 open to participants now, 1 under way, 1 of them phase 3. Vortioxetine · Depressive Disorder, Major.

Enrollment
10th of 54
611 · median 413
Started
2008
with 5 others
Phase 3
31 of 54
1 open now
Registered
3rd of 54
by date
Lead sponsor
17 of 54
Takeda

Among the 54 studies testing vortioxetine in Depressive Disorder, Major, this one is the 10th largest by enrollment, is one of 6 that started in 2008, is one of 31 in phase 3, and was the 3rd registered.

Depressive Disorder, Major

3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

1 of the 54 studies testing vortioxetine in Depressive Disorder, Major is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vortioxetine

Vortioxetine: first FDA approval 2013 (TRINTELLIX), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing vortioxetine in Depressive Disorder, Major, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of vortioxetine, once daily (QD), in adults with major depressive disorder.

Read the detailed description

The drug that was tested in this study is called Vortioxetine. Vortioxetine is being tested to treat depression in adults who have major depressive disorder (MDD). This study looked at MDD relief in people who took varying dosages of vortioxetine.

The study enrolled 611 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the four treatment groups-which remained undisclosed to the patient and study doctor during the study (unless there was an urgent medical need):

  • Vortioxetine 2.5 mg
  • Vortioxetine 5 mg
  • Duloxetine 10 mg
  • Placebo (dummy inactive capsule) - this was a capsule that looked like the study drug but had no active ingredient.

All participants were asked to take one capsule at the same time each day throughout the study.

This multi-center trial was conducted in the United States. The overall time to participate in this study was up to 12 weeks. Participants made 8 visits to the clinic, and were contacted by telephone 4 weeks after the last dose of study drug for a follow-up assessment.

03

Conditions studied

  • Major Depressive Disorder

Keywords

  • Major Depressive Disorder
  • Depression
  • Drug Therapy
  • Major Depressive Episode
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Suffers from a major depressive episode as the primary diagnosis according to , 4th Edition, Text Revision (DSM-IV-TR) criteria.
  • The reported duration of the current major depressive episode is at least 3 months.

Exclusion criteria

Exclusion Criteria:

  • Has 1 or more the following:

    • Any current psychiatric disorder other than major depressive disorder as defined in the .
    • Current or past history of: manic or hypomanic episode, schizophrenia, or any other psychotic disorder, including major depression with psychotic features, mental retardation, organic mental disorders, or mental disorders due to a general medical condition as defined in the DSM-IV-TR.
    • Any substance disorder (except nicotine and caffeine) within the previous 6 months as defined in the DSM-IV-TR.
    • Presence or history of a neurological disorder (including epilepsy).
    • Neurodegenerative disorder (Alzheimer disease, Parkinson disease, multiple sclerosis, Huntington disease, etc).
    • Any Axis II disorder that might compromise the study.
  • Has a significant risk of suicide according to the investigator's opinion or has a score ≥5 on item 10 (suicidal thoughts) of the Montgomery Åsberg Depression Rating Scale (MADRS) or has made a suicide attempt in the previous 6 months.
  • The current depressive symptoms of the patient are considered by the investigator to have been resistant to 2 adequate antidepressant treatments of at least 6 weeks duration each.
  • Has received electroconvulsive therapy within 6 months prior to Screening.
  • Is currently receiving formal cognitive or behavioral therapy, systematic psychotherapy, or plans to initiate such therapy during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
611 participants (actual)

Study arms

  • Experimental
    Vortioxetine 2.5 mg

    Vortioxetine 2.5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.

    Drug: Vortioxetine

  • Experimental
    Vortioxetine 5 mg

    Vortioxetine 5 mg, encapsulated tablets, orally, once daily for up to 8 weeks, then placebo-matching capsules, orally, once daily, for 1 week following the treatment period.

    Drug: Vortioxetine

  • Active comparator
    Duloxetine 60 mg

    Duloxetine 60 mg, capsules, orally, once daily for up to 8 weeks, then duloxetine 30 mg capsules, orally, once daily for 1 week after the treatment period.

    Drug: Duloxetine

  • Placebo comparator
    Placebo

    Placebo-matching capsules, orally, once daily for up to 9 weeks.

    Drug: Placebo

Interventions

  • Encapsulated vortioxetine immediate-release tablets

    Also known as: Lu AA21004, Brintellix®

  • Duloxetine capsules

    Also known as: Cymbalta®

  • DrugPlacebo

    Placebo-matching capsules

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

    The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, and 6

  2. Percentage of Responders in HAM-D 24 Total Score by Study Visit

    A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.

  3. Percentage of Participants With a Sustained Response in HAM-D24

    A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.

    Time frame: Baseline to Week 8

  4. Percentage of Participants in MADRS Remission at Week 8

    Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

    Time frame: Week 8

  5. Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

    The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8

  6. Clinical Global Impression Scale-Global Improvement Scale

    The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.

  7. Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)

    The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 4 and 8

  8. Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

    The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.

  9. Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale

    The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Weeks 1, 2, 4, 6 and 8.

  10. Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

    The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

    Time frame: Baseline and Week 8

  11. Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

    Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

    Time frame: Baseline and Week 8

07

Results

Posted Dec 18, 2013

Participant flow

Participants took part in the study at 47 investigative sites in the United States from 10 April 2008 to 30 December 2008.

Participant flow — Overall Study
MilestonePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Started153153153152
Treated151149153150
Completed12099122110
Not completed33543142
Withdrew: Adverse event771217
Withdrew: Lack of efficacy1220
Withdrew: Noncompliance with study drug3402
Withdrew: Protocol deviations5725
Withdrew: Withdrawal of consent61256
Withdrew: Lost to follow-up819811
Withdrew: Reason not specified3321

Outcome measures

PrimaryChange From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. Least squares (LS) means were from an Analysis of Covariance (ANCOVA) model with terms for treatment and center as factors and the Baseline rank value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8-10.50 ± 0.757-12.04 ± 0.744-11.08 ± 0.737-13.47 ± 0.750
Statistical analysis
  • Placebo vs Vortioxetine 5 mg · ANCOVA · p = 0.577 (Pre-specified sequential statistical testing procedure indicates that when p-value \>0.05, hierarchical testing stops and for subsequent endpoints in the sequence a nominal p-value is provided.) · Ls mean difference: -0.58 · 95% CI -2.61 to 1.46ANCOVA with treatment and center as fixed factors, baseline HAM-D24 as covariate.
  • Placebo vs Vortioxetine 2.5 mg · ANCOVA · p = 0.138 · Ls mean difference: -1.54 · 95% CI -3.58 to 0.50ANCOVA with treatment and center as fixed factors, baseline HAM-D24 as covariate.
  • Placebo vs Duloxetine 60 mg · ANCOVA · p = 0.005 · Ls mean difference: -2.96 · 95% CI -5.02 to -0.91ANCOVA with treatment and center as fixed factors, baseline HAM-D24 as covariate.
SecondaryChange From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed

The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74 where a higher score indicates a greater depressive state. LS means were from an ANCOVA model with terms for treatment and center as factors and the Baseline rank value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, and 6
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Other Weeks Assessed
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=142, 143, 150, 147)-5.12 ± 0.515-5.44 ± 0.497-5.28 ± 0.491-5.66 ± 0.500
Week 2 (n=149, 146, 153, 149)-7.19 ± 0.567-7.95 ± 0.557-7.99 ± 0.552-8.42 ± 0.562
Week 4 (n=149, 146, 153, 149)-9.39 ± 0.663-9.94 ± 0.651-8.96 ± 0.645-10.88 ± 0.657
Week 6 (n=149, 146, 153, 149)-10.43 ± 0.706-11.21 ± 0.694-10.97 ± 0.687-12.78 ± 0.700
SecondaryPercentage of Responders in HAM-D 24 Total Score by Study Visit

A responder is defined as a participant with a ≥50% decrease from Baseline in HAM-D24 total score. The HAM-D24 is a clinician-rated 24-item scale for assessing the severity of depression symptoms. The scores for each item range from 0 to 4 or 0 to 2, where 0 represents no symptoms. The rating is based on the past 7 days prior to the time of assessment. The total score ranges from 0 to 74, where a higher score indicates a greater depressive state.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8.
Reported as:
Number · percentage of participants
Percentage of Responders in HAM-D 24 Total Score by Study Visit
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=142, 143, 150, 147)9.28.48.710.2
Week 2 (n=149, 146, 153, 149)15.417.117.622.1
Week 4 (n=149, 146, 153, 149)26.230.824.234.9
Week 6 (n=149, 146, 153, 149)32.937.737.347.0
Week 8 (n=149, 146, 153, 149)32.241.137.951.0
SecondaryPercentage of Participants With a Sustained Response in HAM-D24

A sustained response is defined as a ≥ 20% decrease from Baseline in HAM-D24 total score obtained at Week 1 and sustained through Week 7 and at least 50% decrease from Baseline at Week 8.

Time frame:
Baseline to Week 8
Reported as:
Number · percentage of participants
Percentage of Participants With a Sustained Response in HAM-D24
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Percentage of Participants With a Sustained Response in HAM-D2412.115.817.021.5
SecondaryPercentage of Participants in MADRS Remission at Week 8

Remission is defined as a participant with a Montgomery Åsberg Depression Rating Scale (MADRS) total score ≤10. The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). Decrease in the total score or on individual items indicates improvement.

Time frame:
Week 8
Reported as:
Number · percentage of participants
Percentage of Participants in MADRS Remission at Week 8
percentage of participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Percentage of Participants in MADRS Remission at Week 822.828.823.537.6
SecondaryChange From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score

The MADRS is a depression rating scale consisting of 10 items, each rated 0 to 6. The 10 items represent the core symptoms of depressive illness. The overall score ranges from 0 (symptoms absent) to 60 (severe depression). A decrease in the total score or on individual items indicates improvement. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Montgomery Åsberg Depression Rating Scale (MADRS) Total Score
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=142, 143, 150, 147)-4.90 ± 0.530-5.16 ± 0.511-5.06 ± 0.505-5.49 ± 0.514
Week 2 (n=149, 146, 153, 149)-7.57 ± 0.615-7.71 ± 0.605-7.81 ± 0.599-8.95 ± 0.609
Week 4 (n=149, 146, 153, 149)-9.66 ± 0.693-9.58 ± 0.681-9.35 ± 0.675-11.34 ± 0.686
Week 6 (n=149, 146, 153, 149)-11.04 ± 0.770-11.25 ± 0.757-11.27 ± 0.750-13.29 ± 0.763
Week 8 (149, 146, 153, 149)-11.22 ± 0.819-11.61 ± 0.805-11.30 ± 0.797-14.10 ± 0.811
SecondaryClinical Global Impression Scale-Global Improvement Scale

The Clinical Global Impression - Global Improvement scale assesses the participant's improvement (or worsening) as assessed by the clinician relative to Baseline on a 7-point scale: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. LS means were from an ANCOVA model with treatment and center as fixed factors and the CGI-S Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8.
Reported as:
Least squares mean · scores on a scale
Clinical Global Impression Scale-Global Improvement Scale
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=142, 143, 149, 147)3.54 ± 0.0673.42 ± 0.0653.46 ± 0.0643.31 ± 0.065
Week 2 (n=149, 146, 153, 149)3.21 ± 0.0773.17 ± 0.0763.10 ± 0.0752.99 ± 0.076
Week 4 (149, 146, 153, 149)2.97 ± 0.0852.93 ± 0.0842.87 ± 0.0832.73 ± 0.084
Week 6 (149, 146, 153, 149)2.83 ± 0.0912.82 ± 0.0902.74 ± 0.0892.50 ± 0.090
Week 8 (n=149, 146, 153, 149)2.79 ± 0.0982.73 ± 0.0962.63 ± 0.0952.39 ± 0.097
SecondaryChange From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)

The MADRS-S is a patient-reported outcome measure based on MADRS, administered to evaluate treatment effectiveness in depression. This scale consists of 9 items assessing patients' mood, feelings of unease, sleep, appetite, ability to concentrate, initiative, emotional involvement, pessimism and zest for life. Each item is scored between 0 (best) and 3 (worst). The total score is calculated by summing the answers of the nine items, ranging between 0 and 27 (higher scores indicate increased impairment). LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 4 and 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Montgomery-Åsberg Depression Rating Scale - Self-assessment (MADRS-S)
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=141, 142, 149, 146)-2.51 ± 0.310-2.43 ± 0.299-2.74 ± 0.295-2.88 ± 0.299
Week 4 (148, 145, 152, 149)-4.02 ± 0.348-3.65 ± 0.342-3.69 ± 0.338-4.89 ± 0.342
Week 8 (n=148, 145, 152, 149)-4.25 ± 0.370-3.98 ± 0.364-4.04 ± 0.360-5.70 ± 0.364
SecondaryChange From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score

The HAM-A is an anxiety rating scale consisting of 14 items that assess anxious mood, tension, fear, insomnia, intellectual (cognitive) symptoms, depressed mood, behavior at interview, somatic (sensory), cardiovascular, respiratory, gastrointestinal, genitourinary, autonomic and somatic (muscular) symptoms. Each symptom is rated from 0 (absent) to 4 (maximum severity). Total scores range from 0 to 56, where \<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores above 30 are rare, but indicate very severe anxiety. LS means are from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=142, 143, 150, 147)-2.63 ± 0.356-2.98 ± 0.343-2.55 ± 0.339-2.30 ± 0.346
Week 2 (n=149, 146, 153, 149)-3.82 ± 0.419-4.41 ± 0.412-3.76 ± 0.408-3.94 ± 0.415
Week 4 (n=149, 146, 153, 149)-5.12 ± 0.457-5.10 ± 0.450-4.25 ± 0.445-4.88 ± 0.454
Week 6 (n=149, 146, 153, 149)-5.84 ± 0.482-5.77 ± 0.474-4.89 ± 0.469-6.15 ± 0.478
Week 8 (n=149, 146, 153, 149)-5.75 ± 0.502-5.91 ± 0.494-5.29 ± 0.488-6.56 ± 0.498
SecondaryChange From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale

The Clinical Global Impression - Severity scale (CGI-S) is a 7-point scale that requires the clinician to rate the severity of the patient's illness at the time of assessment, relative to the clinician's past experience with patients who have the same diagnosis. Considering total clinical experience, a patient is assessed on severity of mental illness on the following scale: 1, normal, not at all ill; 2, borderline mentally ill; 3, mildly ill; 4, moderately ill; 5, markedly ill; 6, severely ill; or 7, extremely ill. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Weeks 1, 2, 4, 6 and 8.
Reported as:
Least squares mean · scores on a scale
Change From Baseline in the Clinical Global Impression Scale-Severity of Illness Scale
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Week 1 (n=142, 143, 150, 147)-0.28 ± 0.055-0.40 ± 0.053-0.37 ± 0.053-0.44 ± 0.054
Week 2 (n=149, 146, 153, 149)-0.63 ± 0.071-0.65 ± 0.069-0.66 ± 0.069-0.75 ± 0.070
Week 4 (n=149, 146, 153, 149)-0.92 ± 0.086-0.92 ± 0.085-0.90 ± 0.084-1.12 ± 0.085
Week 6 (n=149, 146, 153, 149)-1.11 ± 0.094-1.08 ± 0.092-1.08 ± 0.091-1.39 ± 0.093
Week 8 (n=149, 146, 153, 149)-1.14 ± 0.103-1.21 ± 0.102-1.17 ± 0.101-1.56 ± 0.102
SecondaryChange From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8

The Sheehan Disability Scale assesses functional impairment in 3 domains: work/school, social life or leisure activities, and home life or family responsibilities. The participant rates the extent to which each aspect is impaired on a 10-point visual analog scale, from 0 (not at all) to 10 (extremely). The 3 scores are added together to calculate the total score, which ranges from 0 to 30, with higher scores indicating more impairment. LS means were from an ANCOVA model with treatment and center as fixed factors and the Baseline value as a covariate.

Time frame:
Baseline and Week 8
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8
scores on a scalePlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Week 8-6.83 ± 0.638-6.46 ± 0.640-6.59 ± 0.641-8.91 ± 0.672
SecondaryHealthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire

Healthcare resource utilization was assessed by the Health Economic Assessment (HEA) questionnaire, which monitors participants absenteeism from work, as well as resource use such as visits to a general practitioner, outpatient and inpatient services, hospitalization, medications, and other relevant services over the past 8 weeks.

Time frame:
Baseline and Week 8
Reported as:
Number · participants
Healthcare Resource Utilization as Assessed by the Health Economic Assessment Questionnaire
participantsPlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Baseline: Any resource use40514242
Baseline: Any hospitalization-related services4103
Baseline: Hospitalization related to depression2100
Baseline: Any sick leave18111114
Baseline: Sick leave related to depression1391011
Week 8: Any resource use21192027
Week 8: Any hospitalization-related service1012
Week 8: Hospitalization related to depression0001
Week 8: Any sick leave5595
Week 8: Sick leave related to depression2432

Adverse events

Collected over Adverse events were collected during the 8-week treatment period and a 4-week follow-up period.. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—2/151 (1.3%)81/151 (53.6%)
Vortioxetine 2.5 mg—0/149 (0%)83/149 (55.7%)
Vortioxetine 5 mg—3/153 (2%)87/153 (56.9%)
Duloxetine 60 mg—2/150 (1.3%)120/150 (80%)
Most frequent serious events
Most frequent serious events
EventPlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
Acute myocardial infarctionCardiac disorders0/1510/1490/1531/150
Panic attackPsychiatric disorders0/1510/1490/1531/150
DepressionPsychiatric disorders1/1510/1490/1530/150
Abortion inducedSurgical and medical procedures1/1510/1490/1530/150
Atrial fibrillationCardiac disorders0/1510/1491/1530/150
Coronary artery diseaseCardiac disorders0/1510/1491/1530/150
Head injuryInjury, poisoning and procedural complications0/1510/1491/1530/150
ConvulsionNervous system disorders0/1510/1491/1530/150
Most frequent other events
Showing 10 of 34
Most frequent other events
EventPlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mg
NauseaGastrointestinal disorders16/15124/14944/15363/150
Dry mouthGastrointestinal disorders11/15116/14916/15340/150
HeadacheNervous system disorders18/15120/14924/15321/150
DizzinessNervous system disorders7/15110/1499/15322/150
SomnolenceNervous system disorders6/1513/1499/15320/150
DiarrhoeaGastrointestinal disorders13/1517/14914/15319/150
ConstipationGastrointestinal disorders11/1516/1496/15318/150
FatigueGeneral disorders5/1513/1493/15313/150
InsomniaPsychiatric disorders6/1516/1496/15311/150
HyperhidrosisSkin and subcutaneous tissue disorders4/1514/1494/15311/150

Baseline characteristics

Age Continuous
Age Continuous(years)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
Mean42.6 ± 13.7642.6 ± 12.8543.1 ± 13.8942.7 ± 14.3842.7 ± 13.70
Age, Customized
Age, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
≤55 years122127125123497
>55 years31262829114
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
Female939810691388
Male60554761223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
Caucasian (White, including Hispanic)121112108111452
Black28354036139
Asian333312
American Indian or Alaska Native12003
Native Hawaiian/ Other Pacific Islander01012
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
Hispanic/Latino35211928103
Non-Hispanic/Non-Latino118132133123506
Region of Enrollment
Region of Enrollment(participants)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
United States153153153152611
Weight
Weight(kg)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
Mean84.22 ± 20.14485.08 ± 24.12688.61 ± 25.77987.44 ± 20.69586.34 ± 22.823
Height
Height(cm)PlaceboVortioxetine 2.5 mgVortioxetine 5 mgDuloxetine 60 mgTotal
Mean168.98 ± 9.141169.50 ± 9.385167.98 ± 9.833170.37 ± 9.624169.21 ± 9.515

7 further baseline measures are reported on the registry.

08

Study locations

38 sites
  • Beverly Hills, California, United States
  • Irvine,, California, United States
  • Santa Ana, California, United States
  • Torrance, California, United States
  • Upland, California, United States
  • Bradenton, Florida, United States
  • Coral Springs,, Florida, United States
  • Fort Walton Beach, Florida, United States
  • Gainesville, Florida, United States
  • Jacksonville, Florida, United States
  • Maitland, Florida, United States
  • Orlando, Florida, United States
  • South Miami,, Florida, United States
  • West Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Smyrna, Georgia, United States
  • Chicago,, Illinois, United States
  • Libertyville, Illinois, United States
  • Oak Brook, Illinois, United States
  • Prairie Village, Kansas, United States
  • Owensboro,, Kentucky, United States
  • Baltimore, Maryland, United States
  • Pittsfield, Massachusetts, United States
  • Worcester,, Massachusetts, United States
  • Flowood, Mississippi, United States
  • New York, New York, United States
  • Olean, New York, United States
  • Beachwood, Ohio, United States
  • Toledo, Ohio, United States
  • Oklahoma City,, Oklahoma, United States
  • Allenton, Pennsylvania, United States
  • Lancaster, Pennsylvania, United States
  • Memphis, Tennessee, United States
  • Austin, Texas, United States
  • San Antonio, Texas, United States
  • Salt Lake City,, Utah, United States
  • Seattle, Washington, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Mahableshwarkar AR, Jacobsen PL, Chen Y. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 2013 Mar;29(3):217-26. doi: 10.1185/03007995.2012.761600. Epub 2013 Jan 17. PubMed 23252878 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Nov 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2013, 5 years 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2008
First posted
May 6, 2008
Start
Apr 2008
Primary completionActual
Nov 2008
CompletionActual
Dec 2008
Results first posted
Dec 18, 2013
Last update
Dec 18, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 18, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00672620
Lead sponsor
Takeda
Collaborators
H. Lundbeck A/S
Responsible party
Sponsor
First posted
May 6, 2008
Start date
Apr 2008
Primary completion
Nov 2008
Completion
Dec 2008
Results posted
Dec 18, 2013
Last update
Dec 18, 2013

Study contacts

Medical Director, Clinical Science
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vortioxetine

Start the discussion